dc.creator | Gerogianni I., Pitaraki E., Jagirdar R.M., Kouliou O., Giannakou L., Giannopoulos S., Papazoglou E., Hatzoglou C., Gourgoulianis K.I., Zarogiannis S.G. | en |
dc.date.accessioned | 2023-01-31T07:41:20Z | |
dc.date.available | 2023-01-31T07:41:20Z | |
dc.date.issued | 2019 | |
dc.identifier | 10.21873/anticanres.13530 | |
dc.identifier.issn | 02507005 | |
dc.identifier.uri | http://hdl.handle.net/11615/72234 | |
dc.description.abstract | Background/Aim: Malignant pleural mesothelioma (MPM) is a therapy-resistant neoplasm of the pleura. Standard chemotherapy consists of a combination of cisplatin (CPDD) and pemetrexed (PEM). The aim of this study was to assess whether inhibition of aerobic glycolysis by 2-deoxy-glucose (2DG) would enhance the effects of standard chemotherapy. Materials and Methods: MeT-5A, M14K, MSTO and ZL34 cell lines were used. Cell viability with 2DG and cell proliferation and spheroid formation with CPDD+PEM alone and with 2-DG were tested. Results: Viability with 2-DG was dose-dependent. Cell proliferation with CPDD+PEM on 2D surface was reduced in all cell types, 2-DG inclusion demonstrated a synergistic effect in MSTO and ZL34 cells. Spheroid growth in 3D with CPDD+PEM or CPDD+PEM+2-DG lowered spheroid growth in all cell types. Conclusion: 2-DG synergizes with CPDD+PEM in lowering MPM cell proliferation in 2D to <20%. In 3D MPM spheroid growth 2-DG synergism with CPDD+PEM treatment is not maintained. © 2019 International Institute of Anticancer Research. All rights reserved. | en |
dc.language.iso | en | en |
dc.source | Anticancer Research | en |
dc.source.uri | https://www.scopus.com/inward/record.uri?eid=2-s2.0-85068254246&doi=10.21873%2fanticanres.13530&partnerID=40&md5=dbe4394cccebb7c8fe66db86a7486ccb | |
dc.subject | cds 024404 | en |
dc.subject | cisplatin | en |
dc.subject | d 8375 1g | en |
dc.subject | deoxyglucose | en |
dc.subject | pemetrexed | en |
dc.subject | antineoplastic agent | en |
dc.subject | cisplatin | en |
dc.subject | deoxyglucose | en |
dc.subject | pemetrexed | en |
dc.subject | aerobic glycolysis | en |
dc.subject | Article | en |
dc.subject | cancer combination chemotherapy | en |
dc.subject | cell proliferation | en |
dc.subject | cell viability | en |
dc.subject | controlled study | en |
dc.subject | drug potentiation | en |
dc.subject | human | en |
dc.subject | human cell | en |
dc.subject | pleura mesothelioma | en |
dc.subject | priority journal | en |
dc.subject | surface property | en |
dc.subject | tumor spheroid | en |
dc.subject | cell proliferation | en |
dc.subject | cell survival | en |
dc.subject | drug effect | en |
dc.subject | lung tumor | en |
dc.subject | mesothelioma | en |
dc.subject | multicellular spheroid | en |
dc.subject | pleura tumor | en |
dc.subject | tumor cell line | en |
dc.subject | Antineoplastic Agents | en |
dc.subject | Cell Line, Tumor | en |
dc.subject | Cell Proliferation | en |
dc.subject | Cell Survival | en |
dc.subject | Cisplatin | en |
dc.subject | Deoxyglucose | en |
dc.subject | Humans | en |
dc.subject | Lung Neoplasms | en |
dc.subject | Mesothelioma | en |
dc.subject | Pemetrexed | en |
dc.subject | Pleural Neoplasms | en |
dc.subject | Spheroids, Cellular | en |
dc.subject | International Institute of Anticancer Research | en |
dc.title | 2-Deoxy-glucose Enhances the Effect of Cisplatin and Pemetrexed in Reducing Malignant Pleural Mesothelioma Cell Proliferation but Not Spheroid Growth | en |
dc.type | journalArticle | en |